Abstract
Abstract Encouraging innovation by rewarding pharmaceutical patent holders is a key to societal progress, given mandatory disclosure and adequate reimbursement. Following debate on fair prices from a competition law perspective, the recent Health Trade Assessment Regulation provides Member States with a harmonized tool to help them set prices in a more sustainable way. This article discusses the extent to which the Regulation will provide comprehensive access to healthcare as an expression of patient welfare, framing the debate in terms of sustainability.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
